Sepsis Clinical Trial
— PLEASeOfficial title:
Randomized, Double-blind, Placebo-controlled Phase 2a Trial of Efficacy and Safety of Evolocumab for PCSK9 Lowering in Early Acute Sepsis
This study evaluates using evolocumab, a currently approved and marketed biologic drug, in a novel way. Patients who present to the emergency room or intensive care unit (ICU) with severe infection are eligible. Either the patient or their designated decision maker will be approached for consent. If they choose to participate they will be given either a single dose of evolocumab, a higher single dose of evolocumab,or a single dose of placebo. Participants will be followed during their stay in the ICU and will receive follow up phone calls at Day 28 and 90.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | February 11, 2021 |
Est. primary completion date | February 11, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: - Signed informed consent - At least 19 years of age - Known or suspected infection - AND one or more of the following organ dysfunctions judged due to sepsis: 1. Cardiovascular- refractory hypotension (a systolic blood pressure (SBP) < 90 mm Hg or mean arterial pressure (MAP) < 60 mm Hg despite an IV fluid challenge of at least 30 ml/kg fluids), or use of vasopressor(s) to maintain SAP > 90 mm Hg or MAP > 60 mm Hg, or; 2. Respiratory: PaO2/FiO2 < 300 or PaO2/FiO2 < 200 if lung is the only organ dysfunction or SaO2:FiO2 150 Exclusion Criteria: - Known pregnancy - Underlying severe congestive heart failure (New York Heart Association (NYHA) IV), severe COPD (need for chronic oxygen or mechanical ventilation), severe liver disease (Child-Pugh Class C), cancer requiring chemotherapy, or transplantation (bone marrow, heart, lung, liver, pancreas, or small bowel) in the past 6 months or likely within the next 6 months - Previous episode of sepsis during that hospital admission - Absolute Neutrophil Count < 500/mm³ - CD4 count < 50/mm³ - Treating physician deems aggressive care unsuitable (i.e. no commitment to active care) - Participation in another interventional drug study within previous 1 month - Allergic to the study drug or any of its components - Lactation - Have signed a Do No Resuscitate (DNR) Form |
Country | Name | City | State |
---|---|---|---|
Canada | Surrey Memorial Hospital | Surrey | British Columbia |
Canada | St. Paul's Hospital | Vancouver | British Columbia |
Canada | Vancouver General Hospital | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia |
Canada,
Boyd JH, Fjell CD, Russell JA, Sirounis D, Cirstea MS, Walley KR. Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis. J Innate Immun. 2016;8(2):211-20. doi: 10.1159/000442976. Epub 2016 Jan 13. Review. — View Citation
Cirstea M, Walley KR, Russell JA, Brunham LR, Genga KR, Boyd JH. Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis. J Crit Care. 2017 Apr;38:289-294. doi: 10.1016/j.jcrc.2016.11.041. Epub 2016 Dec 7. — View Citation
Levels JH, Abraham PR, van Barreveld EP, Meijers JC, van Deventer SJ. Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect Immun. 2003 Jun;71(6):3280-4. — View Citation
Levels JH, Abraham PR, van den Ende A, van Deventer SJ. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun. 2001 May;69(5):2821-8. — View Citation
Levels JH, Marquart JA, Abraham PR, van den Ende AE, Molhuizen HO, van Deventer SJ, Meijers JC. Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect Immun. 2005 Apr;73(4):2321-6. — View Citation
Roveran Genga K, Lo C, Cirstea M, Zhou G, Walley KR, Russell JA, Levin A, Boyd JH. Two-year follow-up of patients with septic shock presenting with low HDL: the effect upon acute kidney injury, death and estimated glomerular filtration rate. J Intern Med. 2017 May;281(5):518-529. doi: 10.1111/joim.12601. Epub 2017 Mar 19. — View Citation
Topchiy E, Cirstea M, Kong HJ, Boyd JH, Wang Y, Russell JA, Walley KR. Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor. PLoS One. 2016 May 12;11(5):e0155030. doi: 10.1371/journal.pone.0155030. eCollection 2016. Erratum in: PLoS One. 2016;11(7):e0160326. — View Citation
Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada TA, Fjell CD, Thair SA, Cirstea MS, Boyd JH. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med. 2014 Oct 15;6(258):258ra143. doi: 10.1126/scitranslmed.3008782. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the plasma LTA and LPS curves | Determine whether evolocumab decreases plasma levels of bacterial LPS and LTA, at 6, 24, 48 and 72 hours, and day 7 by comparing the area under the operating curve between arms. | 7 days or less (as data is collected from participants only while they are admitted to critical care, they may be discharged or moved to a different ward before day 7 and therefore subsequent time points would be not be collected) | |
Secondary | Levels of LDL-C | Measure levels (concentration; e.g. ug/mL) of low-density lipoprotein-cholesterol (LDL-C) at 24, 48, and 72 hours, and day 7, and compare area under the plasma cytokine curve between arms. | 7 days or less (as data is collected from participants only while they are admitted to critical care, they may be discharged or moved to a different ward before day 7 and therefore subsequent time points would be not be collected) | |
Secondary | Levels of cytokines IL-6, TNF-alpha and IL-8 | Measure levels (concentration; e.g. ug/mL) of cytokines (IL-6, TNF-alpha and IL-8) at 24, 48, and 72 hours, and day 7, and compare area under the plasma cytokine curve between arms. | 7 days or less (as data is collected from participants only while they are admitted to critical care, they may be discharged or moved to a different ward before day 7 and therefore subsequent time points would be not be collected) | |
Secondary | Concentration of circulating evolocumab and circulating free PCSK9 in septic patients | Assess the concentration (e.g. umol/L) of circulating evolocumab and free (unbound by antibody) PCSK9 in evolocumab-treated patients with sepsis and compare to placebo controls. | 7 days or less (may be discharged from critical care before day 7) | |
Secondary | Cmax of circulating evolocumab and circulating free PCSK9 in septic patients | Assess the Cmax of circulating evolocumab and free (unbound by antibody) PCSK9 in evolocumab-treated patients with sepsis and compare to placebo controls. | 7 days or less (may be discharged from critical care before day 7) | |
Secondary | Days alive | Determine if changes in days alive over 28 days are associated with treatment arm. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Changes in 28-day mortality | Determine whether differences in mortality rates at 28 days exist between treatment arms. | 28 days | |
Secondary | Level of organ dysfunction | Determine if changes in days free of organ dysfunction (cardiovascular, respiratory, renal, hematologic, and hepatic) over 28 days are associated with treatment arm. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Level of organ support | Determine if changes in days free of organ support (vasopressor, ventilation and renal replacement therapy (RRT)) over 28 days are associated with treatment arm. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Changes in Vitals: lactate | Determine if changes in plasma lactate levels (mmol/L) are associated with treatment arm. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Changes in Vitals: norepinephrine dose | Determine if changes in norepinephrine levels (mcg/min) are associated with treatment arm. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Changes in Vitals: mean arterial pressure | Determine if changes in mean arterial pressure levels (mm Hg) are associated with treatment arm. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Changes in Vitals: heart rate | Determine if changes in heart rate (beats per minute) are associated with treatment arm. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Changes in Vitals: respiratory rate | Determine if changes in respiratory rate (breaths per minute) are associated with treatment arm. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Changes in Vitals: temperature | Determine if changes in temperature (degrees Celsius) are associated with treatment arm. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Changes in Vitals: fluid balance | Determine if changes in fluid balance (Liters) are associated with treatment arm. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Changes in Vitals: urine output | Determine if changes in urine output (Liters) are associated with treatment arm. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Safety outcomes: Number of treatment-related adverse events as ranked by severity | Monitor and count by category, and evaluate severity and seriousness of any adverse events related to the intervention that occurs in this critical and previously untested population. | Day 1 to Day 90 | |
Secondary | Safety outcomes: changes in blood cell counts | Document changes in blood cell counts (cells/ml) including white blood cells, red blood cells, and platelets, and determine whether clinically significant changes are associated with treatment. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Safety outcomes: changes in coagulation | Document changes in coagulation of blood by measuring Prothrombin Time (PT) and Partial Thromboplastin Time (PTT). Both measurements determine time to clotting (in seconds) of different clotting factors and are then used to calculate International Normalized Ratio (INR) which helps monitor effects of blood thinning medication, and determine whether clinically significant changes are associated with treatment. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Safety outcomes: changes in blood analytes | Document changes in concentration (e.g. umol/mL) of blood analytes, including hemoglobin, glucose, glycated hemoglobin, potassium, sodium, chloride, bicarbonate, creatinine, calcium, triponine, magnesium, aminotransferase, and alanine aminotransferase, and determine whether clinically significant changes are associated with treatment. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Safety outcomes: changes in urine density | Document changes in urine specific gravity (density relative to water) and determine whether clinically significant changes are associated with treatment. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Safety outcomes: changes in urine pH | Document changes in urine pH and determine whether clinically significant changes are associated with treatment. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Safety outcomes: changes in concentration of ketones in urine | Document changes in concentration of ketones (e.g. umol/L) in the urine and determine whether clinically significant changes are associated with treatment. | 28 days or less (may be discharged from critical care before day 28) | |
Secondary | Safety outcomes: document other urine abnormalities if required | Document presence of blood, nitrites, bacteria, or urinary casts in the urine (yes or no) and determine whether clinically significant changes are associated with treatment. | 28 days or less (may be discharged from critical care before day 28) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |